内容紹介
Summary
Case 1 involved a 75-year-old woman with breast cancer and diffuse large B-cell lymphoma(DLBCL). Although we initially administered the R-CHOP regimen, the breast tumor increased in size and surgery had to be performed. After surgery, the R-CHOP regimen was re-initiated and DLBCL achieved clinical complete response. Case 2 involved a 74-year-old woman with breast cancer and gastric MALT lymphoma. After administration of rituximab and H. pylori eradication, a therapeutic effect was achieved in the lymphoma. A docetaxel and FEC regimen was continuously administered and surgery was performed. Case 3 involved a 62-year-old woman with breast cancer and follicular lymphoma. She presented with a history of DLBCL treatment. We performed mastectomy and sentinel lymph node biopsy, which revealed metastasis of breast cancer, and axillary lymph node dissection was subsequently performed. Considering the pathological stage, adjuvant chemotherapy was needed. We selected the TCH regimen based on her past treatment. In conclusion, it is necessary to treat patients with double presentation of breast cancer and malignant lymphoma through cooperation with different departments.
要旨
症例1: 75歳,女性。右乳癌cT2N0M0 StageⅡA,diffuse large B-cell lymphoma(DLBCL) StageⅢA。R-CHOP療法を先行するも,乳癌の増大があり手術を施行した。術後R-CHOP療法を再開し,DLBCLはCR。術後2年経過し,再発所見なし。症例2: 74歳,女性。左乳癌cT0N2M0 StageⅢA,胃MALTリンパ腫 StageⅠ。H. pylori除菌とrituximab投与にて胃MALTリンパ腫は縮小した。docetaxelとFEC療法後,手術を施行した。術後2年経過し,再発所見なし。症例3: 62歳,女性。DLBCL治療歴あり。右乳癌cT1cN0M0 StageⅠ,濾胞性リンパ腫StageⅢA。手術を先行し,センチネルリンパ節に乳癌の転移があり,腋窩郭清術を追加した。右乳癌 pT3N2M0 StageⅢAと診断し,術後TCH療法を選択した。結論: 悪性リンパ腫と乳癌の合併例では血液内科と連携し,症例に応じた治療の組み立てを行うことが重要である。
目次
Case 1 involved a 75-year-old woman with breast cancer and diffuse large B-cell lymphoma(DLBCL). Although we initially administered the R-CHOP regimen, the breast tumor increased in size and surgery had to be performed. After surgery, the R-CHOP regimen was re-initiated and DLBCL achieved clinical complete response. Case 2 involved a 74-year-old woman with breast cancer and gastric MALT lymphoma. After administration of rituximab and H. pylori eradication, a therapeutic effect was achieved in the lymphoma. A docetaxel and FEC regimen was continuously administered and surgery was performed. Case 3 involved a 62-year-old woman with breast cancer and follicular lymphoma. She presented with a history of DLBCL treatment. We performed mastectomy and sentinel lymph node biopsy, which revealed metastasis of breast cancer, and axillary lymph node dissection was subsequently performed. Considering the pathological stage, adjuvant chemotherapy was needed. We selected the TCH regimen based on her past treatment. In conclusion, it is necessary to treat patients with double presentation of breast cancer and malignant lymphoma through cooperation with different departments.
要旨
症例1: 75歳,女性。右乳癌cT2N0M0 StageⅡA,diffuse large B-cell lymphoma(DLBCL) StageⅢA。R-CHOP療法を先行するも,乳癌の増大があり手術を施行した。術後R-CHOP療法を再開し,DLBCLはCR。術後2年経過し,再発所見なし。症例2: 74歳,女性。左乳癌cT0N2M0 StageⅢA,胃MALTリンパ腫 StageⅠ。H. pylori除菌とrituximab投与にて胃MALTリンパ腫は縮小した。docetaxelとFEC療法後,手術を施行した。術後2年経過し,再発所見なし。症例3: 62歳,女性。DLBCL治療歴あり。右乳癌cT1cN0M0 StageⅠ,濾胞性リンパ腫StageⅢA。手術を先行し,センチネルリンパ節に乳癌の転移があり,腋窩郭清術を追加した。右乳癌 pT3N2M0 StageⅢAと診断し,術後TCH療法を選択した。結論: 悪性リンパ腫と乳癌の合併例では血液内科と連携し,症例に応じた治療の組み立てを行うことが重要である。